NeoPhore
Maria is an immunologist with a strong background in immuno-oncology and virology and is passionate about the development of new human cancer immunotherapies. After receiving her PhD in Immunology from the Autonomous University of Barcelona/IrsiCaixa – AIDS Research Institute, she completed her postdoctoral studies at University College London. She later joined the biotech company Tusk Therapeutics where she worked in the development of first-in-class antibody-based therapeutics against cancer. After the acquisition of the company by Roche in 2018, she joined the spin-off Black Belt TX as project leader in the validation of novel immuno-oncology targets and early drug discovery.
NeoPhore
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.